021-51111890
购物车（）
sales@molnova.cn
Pradigastat
CAS No. 956136-95-1
Pradigastat ( —— )
产品货号. M32994 CAS No. 956136-95-1
Pradigastat (LCQ-908) 是一种有效的，选择性的，口服活性的二酰基甘油酰基转移酶 1 (DGAT1) 抑制剂。Pradigastat 具有抗肥胖和抗糖尿病作用。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥1216 | 有现货 |
|
| 5MG | ￥2071 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥2299 | 有现货 |
|
生物学信息
-
产品名称Pradigastat
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Pradigastat (LCQ-908) 是一种有效的，选择性的，口服活性的二酰基甘油酰基转移酶 1 (DGAT1) 抑制剂。Pradigastat 具有抗肥胖和抗糖尿病作用。
-
产品描述Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects.
-
体外实验Pradigastat inhibits breast cancer resistance protein (BCRP)-mediated efflux activity in a dose-dependent fashion in a BCRP over-expressing human ovarian cancer cell line with an IC50 value of 5 μM. Pradigastat inhibits OATP1B1, OATP1B3, and OAT3 activity in a concentration-dependent manner with estimated IC50 values of 1.66 μM, 3.34 μM, and 0.973 μM, respectively.
-
体内实验Pradigastat (LCQ-908) inhibits the postprandial triglyceride levels in rats, dogs and monkeys. In rats whose lipoprotein lipase (LPL) activity has been abolished, Pradigastat reduces the postprandial accumulation of plasma triglyceride. Pradigastat decreases the postprandial rate of chylomicron triglyceride (CM-TG) secretion into the lymphatic duct and reduces the size of chylomicrons.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点Transferase
-
受体Transferase
-
研究领域——
-
适应症——
化学信息
-
CAS Number956136-95-1
-
分子量455.47
-
分子式C25H24F3N3O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 62.5 mg/mL (137.22 mM; 超声助溶 (<60°C)；H2O 中的溶解度 : < 0.1 mg/mL (insoluble)
-
SMILESOC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Meyers CD, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015 Feb 18;14:8.?
